Clinical trials: Neoplasms, Metastatic
Melanoma
Trial of pIL-12/MK-3475 in Metastatic Melanoma
This is a multicenter, Phase II, open-label, 42-patient single-arm trial of intratumoral pIL-12 electroporation (EP) in combination with pembrolizumab in patients with melanoma. Patients will be evaluated in 2 parts.
- Trial name
- NCT02493361
- Testing
- Pembrolizumab, pIL-12
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Metastatic Castration-resistant Prostate Cancer
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
- Trial name
- NCT07213674
- Testing
- Xaluritamig, Abiraterone acetate, Docetaxel
- Where
- 159 sites in United States, Australia and 16 more
- Volunteers
- 750 people
- Sponsor
- Amgen
Myeloma Multiple, Metastatic Bone Tumor
CTFEA Myeloma Study
Patients with Multiple Myeloma are monitored for disease progression and for response to treatment by the treating hematologist or oncologist. Laboratory tests are usually utilized for these purposes.
- Trial name
- NCT04364724
- Testing
- CT-based finite element analysis
- Volunteers
- 200 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Metastatic Cancer
Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00006259
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma
A Phase 2 Clinical Study of ABSK061 and ABSK043
The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
- Conditions
- HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
- Trial name
- NCT06632262
- Testing
- ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX
- Where
- 21 sites in China
- Volunteers
- 202 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Colorectal Cancer
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the…
- Trial name
- NCT00118261
- Testing
- bevacizumab, erlotinib hydrochloride, fluorouracil
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Case Comprehensive Cancer Center
Lung Tumor, Metastatic Cancer
A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm
This is a phase 0, pilot prospective study to determine the feasibility of combined irreversible electroporation (IRE) and radiation therapy in subjects with lung tumors with metastatic cancer of any histology.
- Trial name
- NCT05555342
- Testing
- Irreversible electroporation (IRE) ablation, Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Irvine
Soft Tissue Sarcomas, Angiosarcoma
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
This study will enroll patients with specific subtypes of unresectable or metastatic soft tissue sarcoma, and will combine tislelizumab with the standard chemotherapy of liposomal doxorubicin and ifosfamide to initially explore…
- Conditions
- Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma, Leiomyosarcoma
- Trial name
- TAIS (NCT06849986)
- Testing
- Tislelizumab+liposomal doxorubicin+ifosfamide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Laparoscope Anatomical and Aon-anatomical Hepatectomy
The purpose of this study is to compare short-term and long-term efficacy of two surgical methods by laparoscopic hepatectomy, and provide the evidence for the choice of surgical method from the pathology and cytology.
- Trial name
- NCT02009176
- Testing
- Laparoscopic Anatomical Hepatectomy, Laparoscopic Aon-anatomical Hepatectomy
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Shuguo Zheng, MD
Liver Metastasis Colon Cancer
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases
- Trial name
- NCT04832776
- Testing
- Cetuximab, Bevacizumab, FOLFOXIRI
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Colorectal Cancer
Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.
The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly. The genome analysis needs systematic infra and database based on personal genetic information.
- Trial name
- NCT02593591
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Cancer, Metastatic, Pain, Chronic
Mindfulness for Pain Management in Patients With Cancer
Using pharmacologic agents are often effective to treat patients with cancer pain, but there are associated with serious side-effects and risks of dependence and addiction.
- Trial name
- NCT03351010
- Testing
- Mindfulness training program, Cancer pain educational program
- Where
- Thailand
- Volunteers
- 17 people
- Sponsor
- University of Michigan
Metastatic Colorectal Cancer
Adjuvant Aflibercept for Metastatic Colorectal Cancer
The main purpose of this study is to evaluate if aflibercept can reduce the chance that metastatic (spread of) colorectal cancer can grow back after finishing standard treatment.
- Trial name
- C261 (NCT01669720)
- Testing
- Aflibercept
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Brown University
HER2-positive Metastatic Breast Cancer
Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
This is an open-label, multicenter, dose-escalation and parallel-group expansion Phase II clinical trial to evaluate the efficacy, safety and tolerability of KN026 in combination with palbociclib and fulvestrant in women or male…
- Trial name
- NCT04778982
- Testing
- KN026 combined with Palbociclib and Fulvestrant
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Metastatic Breast Cancer
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.
- Trial name
- NCT06081959
- Testing
- SKB264, Eribulin, Capecitabine
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Congestive Heart Failure, Metastatic Cancer
Advance Care Planning in the Emergency Department
This is a two-armed, parallel-design, pre-/post-intervention assessment study. The investigators will conduct a randomized controlled trial for ED GOAL on a cohort of 120 older adults with serious illness to collect…
- Conditions
- Congestive Heart Failure, Metastatic Cancer, Chronic Kidney Disease Requiring Chronic Dialysis, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05209880
- Testing
- ED GOAL
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Brigham and Women's Hospital
Cancer
Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor
In mouse models and in patients, expression of the chemokine receptor CXCR4 on various cancers has been correlated with aggressive biological behavior, including increased rates and certain sites of metastasis, and decreased…
- Trial name
- NCT02069080
- Testing
- 64-Cu-plerixafor
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Safety
Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab
Evaluate the objective response rate (ORR) of AK104 combined with chemotherapy and cetuximab or bevacizumab in second-line treatment of MSS type advanced colorectal cancer
- Trial name
- NCT07253896
- Testing
- AK104 and cetuximab or bevacizumab and FOLFIRI
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophageal Neoplasm
Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
In patients with esophageal cancer, treatment with curative intent can be given to medically fit patients without distant metastases. It may consist of chemoradiotherapy or surgery alone or in combination.
- Trial name
- LERFOX-C (NCT02636088)
- Testing
- Cetuximab
- Volunteers
- 51 people
- Sponsor
- Gabriella Alexandersson von Döbeln
Metastatic Cancer, Colorectal Cancer
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
The phase I/II study was designed to evaluate if the regimen of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab is a superior first-line option for patients with metastatic colorectal cancer(mCRC) in terms of…
- Conditions
- Metastatic Cancer, Colorectal Cancer, Colorectal Adenocarcinoma
- Trial name
- NCT04380103
- Testing
- XELOXIRI/Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 106 people
- Sponsor
- Chinese Academy of Medical Sciences
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.